We are honoured to welcome Tuomo Pätsi to Aurealis Therapeutics Board of Directors! Tuomo brings invaluable expertise in clinical strategy, global commercialization, and market access. 🔗 Read the press release: aurealistherapeutics.com/tuomo-patsi-ne…

How did Aurealis Therapeutics achieve the PRIME designation for AUP-16 for the treatment of non-healing #DiabeticFootUlcers? Our Head of Quality and Regulatory Affairs, Hanna-Riikka, shares the journey and team effort that led to achieving this milestone for AUP-16.

Aurealis Therapeutics has successfully completed patient recruitment in the DIAMEND Phase 2 #DiabeticFootUlcer (DFU) #clinicaltrial for AUP-16! 🎉 🔗 For more details, read the full press release: aurealistherapeutics.com/aup-16-dfu-pha…

Aurealis Therapeutics is participating in the LSX World Congress USA on September 11-12, 2024! We are very excited to connect with investors and partners to explore potential collaborations. See you there! 🔗 Let’s meet: partneringone.informaconnect.com/sign-in?eventI… 💬 Get in touch: aurealistherapeutics.com/contact/

Aurealis Therapeutics is proud to sponsor and participate in the 15th Pisa International Diabetic Foot Course 2024, which starts today! 🇮🇹 We look forward to engaging with experts in the field and continuing to drive forward innovative solutions for #ChronicWounds.

Aurealis Therapeutics will be participating at #BIOEurope 2024 in Stockholm, Sweden! 🇸🇪 Our CEO, Juha Yrjänheikki, and COO, Laurent DECORY, are looking forward to connecting with fellow industry leaders, investors, and potential partners to explore new collaboration opportunities.

Aurealis Therapeutics is proud to announce that the last patient in its DIAMEND #AUP16 Phase 2 #ClinicalTrial on non-healing #DFUs has completed treatment. 🎉 🔗Read press release: aurealistherapeutics.com/aup-16-dfu-pha…

Our team at Aurealis Therapeutics is ready for #BIOEurope 2024, will we see you there? 🚀 🔗 Book a meeting: partneringone.informaconnect.com/sign-in?eventI… 🔗 Register here: informaconnect.com/bioeurope/ 🔗 Contact us: aurealistherapeutics.com/partnering/#co…

Aurealis Therapeutics will open 2025 with the team’s participation at the #BiotechShowcase, a leading life science conference! 🎉 Are you interested in partnering with us or learning more about our multi-target innovative platform? Let’s meet in San Francisco!

Aurealis Therapeutics celebrates women and girls in science! 🌍🔬 On the #InternationalDayofWomenandGirlsinScience, we recognize and celebrate the contributions of women shaping the future of science, and in our case, of the #biotechnology industry.

Aurealis Therapeutics is at INV€$TIVAL SHOWCASE USA! 🇺🇸 Our CEO Juha Yrjänheikki is in Miami connecting with key investors & partners at North America's premier biotech & MedTech networking event. After an exciting first day, we're looking forward to more insightful discussions today!

Aurealis Therapeutics First Industry-Sponsored Symposium at #EWMA2025! This exclusive session will present the latest insights on AUP-16, our novel 4-in-1 multi-targeting therapy for non-healing Diabetic Foot Ulcers (DFUs) and “DIAMEND” Phase-2 study.

Aurealis Therapeutics is at SwissBiotech Day 2025 🌍 Our COO, Laurent Decory, is representing #AurealisTherapeutics at the #SwissBiotechDay. This year, Laurent will also participate in the Microbiome Innovators session, pitching our 4-in-1 multi-targeting technology.